UroMems was founded in 2011 and focuses on designing, developing and commercializing active implantable medical devices.
The company is based at the heart of the French Alps, in the city of Grenoble, representing one of the most dynamic French area in the Medtechs industry.
UroMems is highly innovative and focuses on clearly identified clinical unmet needs, not only for their prevalence but also for their negative impact on patient’s quality of life.
Since the inception of the company, significant investments have been made for the development of the UroMems’ first product. This includes a € 12 million series A financing round led by Wellington Partners, Munich, Germany, Bpifrance via FABS Fund, Cita Investissement, Supernova Invest and b-to-v Partners AG.
UroMems’s mission is to offer implantable solutions that are:
In a particularly demanding economic and regulatory context, the company’s ambition is to improve current surgical treatments for helping as many patients as possible, particularly by reducing associated side effects.
In order to fullfil this ambition, UroMems evolves in a leading-edge technology environment and has established partnerships with internationally renowned experts, research laboratories and industrial partners.
Led by the founders’ vision, UroMems follows the strictest ethics.